- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01345084
Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab (NICAP)
A Phase III Study Evaluating the Standard Radiation Therapy and Chemotherapy Regimen, With or Without Nimotuzumab, in Unresectable, Locally Advanced Epidermoid Carcinoma of the Head and Neck
Primary: to compare the overall survival defined as the time elapsed between the randomization date and death due to any cause, in both treatment groups.
Secondary: to compare the progression-free survival, incidence of locoregional failure, site of the first recurrence/progression, objective response rate assessment, quality of life assessment and incidence of adverse events.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a phase III, superiority, national, open-label, randomized, and two-arm study.
Patients' enrollment will be performed only after approval by competent regulatory authorities and it will last up to 12 months.
All patients taking part in the study must sign an informed consent. The patients will have stage III or IV, unresectable head and neck SCC, performance status 0 or 1.
Randomization and treatment assignment will be performed by a company specifically contracted for such purpose and will be per research site and disease stage, 1:1
Studietype
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Rio de Janeiro, Brasil, 210041-030
- Hospital Federal de Bonsucesso
-
São Paulo, Brasil, 01246-000
- Instituto do Câncer de São Paulo
-
-
Paraná
-
Curitiba, Paraná, Brasil, 81520-060
- Hospital Erasto Gaetner
-
-
Rio Grande do Sul
-
porto Alegre, Rio Grande do Sul, Brasil, 90035-903
- Hospital de Clínicas de Porto Alegre
-
-
São Paulo
-
Barretos, São Paulo, Brasil, 14784-400
- Fundacao Pio XII - Hospital de Cancer de Barretos
-
Jau, São Paulo, Brasil, 17210-120
- Hospital Amaral Carvalho
-
Mogi das Cruzes, São Paulo, Brasil, 08730-500
- Centro Oncológico de Mogi das Cruzes
-
São José do Rio Preto, São Paulo, Brasil, 15090-000
- Hospital de Base São José do Rio Preto
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria
- Aged 18 to 75 years old;
- Histological or cytological confirmation of SCC in oral cavity, oropharynx, hypopharynx, or larynx;
- Stages III or IV disease
- Unresectability according to responsible surgeon or medical staff's opinion;
- Performance status 0 or 1
- Present indication for radiation therapy and chemotherapy treatment with cisplatin;
- Adequate hepatic, renal and medullar functions, indicated by:
- Life expectancy above 6 months.
Exclusion Criteria
- Presence of nasopharyngeal, paranasal sinuses, or salivary glands carcinoma;
- Presence of known distant metastasis;
- Presence of any other active neoplasm or history of any tumor diagnosed in the last 5 years
- Patients with inability to eat normally, in whom a gastric or enteral tubing was not possible at least 2 weeks before their enrollment in the study;
- Previous treatment with chemotherapy, radiation therapy, or EGFR inhibitors of any pharmacological class;
- Presence of serious comorbidity that, in the investigator's opinion, will put the patient at risk or will jeopardize protocol compliance;
- Active known seropositivity for HIV, hepatitis B or C
- Presence of a significant neurological or psychiatric disease, as per the investigator's judgment;
- Hypersensitivity or allergy to any of the study treatments;
- Presence of uncontrolled hypercalcemia;
- Pregnancy or breastfeeding;
- Female patients of childbearing potential who wish to become pregnant or are unwilling, as well as their partners, to use an appropriate contraceptive method throughout the study period;
- Participation in any clinical trial in the last 12 months.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Radiation therapy, cisplatin and nimotuzumab
Nimotuzumab - (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes. Pre-drugs are optional, at the investigator's discretion)- 200 mg, IV, weekly doses during the radiation therapy until completing 6 months. Radiation therapy- 66 -70 Gy, external,fractions of 2 Gy per day, 5 days a week Cisplatin - 75 mg/m2, IV, Doses every 3 weeks (a total of three doses) |
200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
|
Aktiv komparator: Radiation therapy and cisplatin
Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses) |
66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
75 mg/m2, IV, doses every 3 weeks (a total of three doses)
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Overall survival
Tidsramme: 6 months
|
Local control of disease will be measured by magnetic resonance imaging (MRI) and physical examination 6 weeks after treatment end.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Complete clinical response rate
Tidsramme: 2 years
|
Progression-free survival; Incidence of locoregional failure; Site of the first recurrence or progression; Objective response rate assessment; EORTC quality of life questionnaires assessment; Incidence of several adverse events;
|
2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Gustavo Girotto, Hospital de Base São José do Rio Preto
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- EF 118
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nimotuzumab
-
Peking UniversityBiotech Pharmaceutical Co., Ltd.Ukjent
-
Peking Union Medical College HospitalHar ikke rekruttert ennå
-
Cancer Institute and Hospital, Chinese Academy...UkjentMagekreft | Samtidig kjemoradioterapiKina
-
Oncoscience AGHeinrich-Heine University, Duesseldorf; University of Kiel; Johann Wolfgang... og andre samarbeidspartnereFullført
-
University of SaskatchewanRekrutteringTykktarmskreft | LungekreftCanada
-
Oncoscience AGHeinrich-Heine University, Duesseldorf; University of Wuerzburg; Children... og andre samarbeidspartnereFullført
-
University of SaskatchewanWestern Economic Diversification CanadaRekruttering
-
YM BioSciencesCIMYM BioSciencesAvsluttetMetastatisk ikke-småcellet lungekreftForente stater, Korea, Republikken, Canada, Cuba, Pakistan
-
The First Affiliated Hospital of Zhengzhou UniversityHar ikke rekruttert ennåEsophageal plateepitelkarsinomKina
-
Biotech Pharmaceutical Co., Ltd.UkjentNasofaryngealt karsinomKina